(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 1 803 809 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
19.12.2007 Bulletin 2007/51

(43) Date of publication A2:
04.07.2007 Bulletin 2007/27

(21) Application number: **06291283.7**

(22) Date of filing: **08.08.2006**

(51) Int Cl.:
C12N 9/02 *(2006.01)* ***C07K 16/40*** *(2006.01)*

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

(30) Priority: **12.08.2005 US 707897 P**

(71) Applicant: **Abgenomics Corporation**
Taipei, Taiwan 114 (TW)

(72) Inventors:
- **Lin, Rong Wha**
  Da-an District, Taipei, Taiwan 106 (CN)
- **Chuang, Lee-Ming**
  Xindian City, Taipei Country, Taiwan 231 (CN)

(74) Representative: **Nargolwalla, Cyra et al**
Cabinet Plasseraud
52 rue de la Victoire
75440 Paris Cedex 09 (FR)

(54) **Modulation of peroxisome proliferator-activated receptors**

(57) A method of treating a peroxisome proliferators-activated receptors related disease by administering to a subject in need thereof an effective amount of a modulator of 15-keto prostaglandin-Δ^{13}-reductase. Also disclosed are methods of identifying a compound for inhibiting activity of the reductase and of lowering blood glucose levels by administering to a subject an effective amount of a reductase inhibitor.

EP 1 803 809 A3

European Patent Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application Number EP 06 29 1283

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 00/71679 A (INCYTE GENOMICS INC [US]; YUE HENRY [US]; TANG Y TOM [US]; BAUGHN MARI) 30 November 2000 (2000-11-30) * claims 1,10; sequence 6 * -----	1-9	INV. C12N9/02 C07K16/40
X	WO 01/79489 A2 (MILLENNIUM PHARM INC [US] MILLENNIUM PHARM INC [US]; MEYERS RACHEL E []) 25 October 2001 (2001-10-25) * page 30, line 23 - line 32; claim 14; figure 1; sequence 2 * * page 49, line 12 - line 30 * * page 63, line 12 - line 13 * * page 70, line 20 - line 32 * -----	1-10,14, 18-27	
X	DATABASE Geneseq [Online] 6 November 2003 (2003-11-06), "Human alcohol dehydrogenase related protein 1 (Adhr-1)." XP002432633 retrieved from EBI accession no. GSP:ADA09101 Database accession no. ADA09101 * the whole document * ----- -/--	1-6	

TECHNICAL FIELDS SEARCHED (IPC)

C07K
C12N

INCOMPLETE SEARCH

The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.

Claims searched completely :

Claims searched incompletely :

Claims not searched :

Reason for the limitation of the search:

see sheet C

Place of search	Date of completion of the search	Examiner
Munich	7 November 2007	Bochelen, Damien

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C07)

European Patent Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 06 29 1283

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	TAI H-H ET AL: "Prostaglandin catabolizing enzymes" PROSTAGLANDINS, BUTTERWORTH, STONEHAM, MA, US, vol. 68-69, August 2002 (2002-08), pages 483-493, XP004380643 ISSN: 0090-6980 * the whole document *	1-9	
X	US 4 591 600 A (CREUZET MARIE-HELENE [FR] ET AL) 27 May 1986 (1986-05-27) * column 6, line 51 - line 52; claims 1,2; examples 1,2 *	10,14, 16,17, 19-24	
X	EP 0 467 564 A (UENO SEIYAKU OYO KENKYUJO KK [JP]) 22 January 1992 (1992-01-22) * page 2, line 58 - page 3, line 2; claim 1 *	10-14,19	TECHNICAL FIELDS SEARCHED (IPC)
X	US 2004/259813 A1 (ZI XIOLIN [US] ET AL) 23 December 2004 (2004-12-23) * paragraph [0038]; claim 1 *	10,14, 16,17,19	
X	EP 0 455 448 A (UENO SEIYAKU OYO KENKYUJO KK [JP]) 6 November 1991 (1991-11-06) * page 3, line 3; claim 1 *	10-14,19	
X	US 4 587 260 A (SMERBECK RICHARD V [US] ET AL) 6 May 1986 (1986-05-06) * column 2, line 41; claims 1,8 *	10,14,16	
X	WO 01/70233 A (UENO SEIYAKU OYO KENKYUJO KK [JP] SUCAMPO AG [CH]) 27 September 2001 (2001-09-27) * page 24, lines 14,16; claim 15 *	10-14,19	

-/--

6

EPO FORM 1503 03.82 (P04C10)

European Patent Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 06 29 1283

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 01/80855 A (GERON CORP [US]; CHIN ALLISON C [GB]; TOLMAN RICHARD L [US]; GRYAZNOV) 1 November 2001 (2001-11-01) * page 17, line 12 - line 23; example 1 * -----	10,14, 16,19	TECHNICAL FIELDS SEARCHED (IPC)

EPO FORM 1503 03.82 (P04C10)

European Patent Office

INCOMPLETE SEARCH SHEET C

Application Number
EP 06 29 1283

Although claims 10-24 and 30-39 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compounds.

Claim(s) searched completely:
11-13, 15-18,23-24

Claim(s) searched incompletely:
10,14,19-22

Claim(s) not searched:
-

Reason for the limitation of the search:

The present claims 10,14,22 encompass compounds defined only by their desired function i.e. PGR3/ZADH2 modulation, contrary to the requirements of clarity of Article 84 EPC, because the result-to-be-achieved type of definition does not allow the scope of the claim to be ascertained. The fact that any compound could be screened does not overcome this objection, as the skilled person would not have knowledge beforehand as to whether it would fall within the scope claimed, except for the compounds disclosed in claims 11-13, 15-17. Undue experimentation would be required to screen compounds randomly. This non-compliance with the substantive provisions is to such an extent, that a meaningful search of the whole claimed subject-matter of the claims could not be carried out (Rule 45 EPC).

The search of claims 10,14,22 was consequently restricted to the specific compounds disclosed in claims 11-13, 15-18.

European Patent Office

Application Number
EP 06 29 1283

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

☒ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

1-29

☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

European Patent Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 06 29 1283

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-9

   Isolated polypeptide comprising a sequence of SED ID NO:1 or SEQ ID NO:3 and antibody binding to the polypeptide

   ---

2. claims: 10-29

   Method for treating a PPAR-related disease or lowering blood glucose levels with a modulator e.g. inhibitor of PGR3/ZADH2, e.g. a dsRNA and method for identifying a compound for inhibiting activity of PGR3/ZADH2

   ---

3. claims: 30-32

   Method for treating a PPAR-related disease with a compound of formula (I)

   ---

4. claims: 33-34

   Method for treating a PPAR-related disease with a compound of formula (II)

   ---

5. claims: 35-38

   Method for treating a PPAR-related disease with a compound of formula (III)

   ---

6. claim: 39

   Method for treating a PPAR-related disease with compounds of claim 39.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO. EP 06 29 1283

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-11-2007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0071679 A	30-11-2000	AU 5034200 A	12-12-2000
		CA 2374413 A1	30-11-2000
		EP 1183370 A2	06-03-2002
		JP 2003517288 T	27-05-2003
WO 0179489 A2	25-10-2001	AU 5166801 A	30-10-2001
		EP 1402026 A2	31-03-2004
US 4591600 A	27-05-1986	CA 1253511 A1	02-05-1989
		DE 3461466 D1	15-01-1987
		EP 0121489 A1	10-10-1984
		ES 8504164 A1	01-07-1985
		FR 2543550 A1	05-10-1984
		JP 59184173 A	19-10-1984
		MA 20086 A1	31-12-1984
		OA 7695 A	23-05-1985
		PT 78340 A	01-04-1984
		ZA 8402402 A	28-11-1984
EP 0467564 A	22-01-1992	AT 137116 T	15-05-1996
		CA 2046069 A1	11-01-1992
		DE 69118978 D1	30-05-1996
		DE 69118978 T2	14-11-1996
		DK 467564 T3	13-05-1996
		ES 2089136 T3	01-10-1996
		GR 3019760 T3	31-07-1996
US 2004259813 A1	23-12-2004	NONE	
EP 0455448 A	06-11-1991	AT 174221 T	15-12-1998
		CA 2041417 A1	02-11-1991
		DE 69130586 D1	21-01-1999
		DE 69130586 T2	17-06-1999
		US 5164415 A	17-11-1992
US 4587260 A	06-05-1986	CA 1236028 A1	03-05-1988
WO 0170233 A	27-09-2001	AR 030275 A1	20-08-2003
		AU 3955101 A	03-10-2001
		CA 2403086 A1	27-09-2001
		CN 1443070 A	17-09-2003
		EP 1267882 A2	02-01-2003
		JP 2003527430 T	16-09-2003
		NZ 521464 A	24-09-2004
WO 0180855 A	01-11-2001	AU 5569601 A	07-11-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82